KDR and nonpapillary renal cell carcinoma: Although VEGF/VEGFR-targeted therapies and immune checkpoint blockade (ICB) have improved patient outcomes over the past decade, the majority of patients eventually develop resistance, underscoring the urgent need to identify novel vulnerabilities and strategies to overcome therapeutic failure in ccRCC.